Clinical Trials Directory

Trials / Completed

CompletedNCT02238392

Adenosine vs AF Termination for Paroxysmal AF Ablation

Arrhythmia Inducibility Versus Elimination of Dormant PV Conduction as a Procedural Endpoint of Catheter Ablation for Paroxysmal Atrial Fibrillation: a Prospective Randomized Trial

Status
Completed
Phase
N/A
Study type
Interventional
Enrollment
150 (actual)
Sponsor
Johannes Gutenberg University Mainz · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

This study investigates impact of adenosine versus AF inducibility and subsequent termination on the acute and long-term outcome of paroxysmal AF ablation.

Detailed description

Despite intensive efforts to increase single procedure success rates of pulmonary vein isolation (PVI) for paroxysmal atrial fibrillation (AF), an arrhythmia-free surveillance has not raised beyond 80%. This prospective, randomized study investigates the efficacy of two different procedural endpoints in terms of single-procedure arrhythmia-free outcome. A total number of 152 patients undergoing de-novo catheter ablation for paroxysmal AF will be randomized to two different treatment arms. In group-A patients, PVI will be performed with the patient either in spontaneous or induced AF. If AF will not terminate with PVI, ablation will be continued by targeting extra-PV AF sources with the desired endpoint of termination to sinus rhythm (SR). The ablation procedure in group-B patients consists of PVI exclusively, regardless to the underlying rhythm. In this group, all isolated PVs will be challenged to adenosine administration in the attempt to reveal and ablate dormant conduction. The primary endpoint is arrhythmia-free survival during a follow-up of 1 year.

Conditions

Interventions

TypeNameDescription
PROCEDUREAdenosine testTesting dormant conduction after PVI
PROCEDURETermination of AFTesting AF iducibility and ermination of

Timeline

Start date
2012-01-01
Primary completion
2014-06-01
Completion
2014-06-01
First posted
2014-09-12
Last updated
2014-09-12

Locations

1 site across 1 country: Germany

Source: ClinicalTrials.gov record NCT02238392. Inclusion in this directory is not an endorsement.